September 01, 2026
Law360 Healthcare Authority looks at a Fifth Circuit ruling backing the removal of certain GLP-1 medications from the national drug shortage list, the dismissal of AstraZeneca's challenge to a Colorado law affecting drug distribution under the federal 340B drug discount program and other litigation outcomes impacting the healthcare industry.
August 27, 2026
The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the Fifth Circuit ruled Thursday, handing a loss to compounding pharmacies that produce copycat doses of the drugs.
March 31, 2026
Law360 Healthcare Authority looks at appellate arguments from compounding pharmacies alleging they were wrongly barred from making their own versions of weight loss drugs, the Federal Trade Commission's suit over an alleged “rollup” of Texas anesthesiology practices, and other significant litigation developments this week.
March 30, 2026
A Fifth Circuit panel pushed multiple compounding pharmacies to explain why they should get to compound lucrative drugs used for weight loss, including Ozempic, saying Monday that its options if it sides with the pharmacies are "tough pills to swallow."